about
sameAs
SATB2 augments ΔNp63α in head and neck squamous cell carcinomaMolecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemiaIdentification of a microRNA signature associated with progression of leukoplakia to oral carcinomaPostal survey of physicians and laboratories: practices and perceptions of molecular oncology testingMolecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss.A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.microRNA evaluation of unknown primary lesions in the head and neckImproving molecular testing and personalized medicine in non-small-cell lung cancer in OntarioOptimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples.Low prevalence of human papillomavirus in oral cavity carcinomas.mRNA transcript quantification in archival samples using multiplexed, color-coded probes.Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence.Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma.Abnormal DNA content in oral epithelial dysplasia is associated with increased risk of progression to carcinoma.Phase II study of PX-866 in recurrent glioblastoma.Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.Erlotinib in lung cancer - molecular and clinical predictors of outcome.Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey.The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomasCanadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.Current applications of microarrays in head and neck cancer research.Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation.Molecular genetic analysis of oligodendroglial tumors.Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.Equivocal p16 immunostaining in squamous cell carcinoma of the head and neck: staining patterns are suggestive of HPV status.Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patientsA model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice.Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemiaA phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
P50
Q24299322-E6EA795C-8132-4976-B227-78D974A302E8Q27852608-1BE288B1-2C5E-4008-AA3D-562DED9773E7Q28248385-4B0AA091-8652-4FC0-A212-3E1FDEC4A403Q28259466-136D2FC3-2198-4EBF-8CDE-82922011C3CAQ30227715-82781BE3-F86C-4DC6-ACB4-ABAC505709A0Q30826387-93D33ED6-CD24-4267-8691-3584047092FCQ33183485-B3A83CB6-99A5-4AC0-9C55-494A38609414Q33402939-02456E67-01A7-4614-ADD8-D0EE61005664Q33415009-18A1F3CC-59BA-4473-8C03-994A294C4672Q33513801-454C25B0-C038-4527-8231-7EDDB9D1E987Q33592209-065E8EAB-CD56-44EA-A1CD-F3AF1EDB5C14Q33611088-39B2AE7D-420F-4CA0-97B6-B6C80C11C79CQ33614363-8C9FF82D-EFCD-4B6F-A453-B365121E84BCQ33776939-ACC4C0ED-82A3-40A5-AABB-DC74AA87A0BFQ33891675-53B0B381-1953-46E8-AF7E-590D96256EBBQ34022596-649B5E08-8DCB-4CF1-ACBB-BAAFC967EEA9Q34033475-6255F98F-7B28-4600-B09C-3411985A04E0Q34046527-43A17C2A-6A67-4A4A-8E92-C1CC3BE0DE69Q34174271-C0259DC8-8CC2-44F5-B29D-11AD379170E2Q34344115-10929E3B-BB71-4675-8E0B-383A53CB4AD9Q34458889-935386D8-1DC9-4D30-85F8-267C117602DEQ34484052-51A3D222-C24E-4948-8FBB-53562076A7B5Q34559274-FE0EA132-C97F-4DBB-A719-14E66C7B2151Q34602163-33E53291-05C2-408E-B481-EFBDB013B624Q34639763-80A90B07-18A6-4BB4-819E-7F92CE75885FQ34929092-B10BFE5F-A19D-4B36-A14C-83DF6813594DQ35145683-5274CF37-6295-4AB6-BBF8-C54B3C961656Q35172203-E45727D2-84EF-47D3-B1DB-7948FC53F81FQ35644986-69CB9267-42E7-424B-A213-C2AEEDE9C1ECQ35849776-A16FAB31-3611-4E1C-8658-05C30D22EE9DQ36000269-C11F5227-05A9-42AD-A2ED-3DF8A6792E10Q36044175-291A57CC-882C-4CF6-9BEA-3916E337C573Q36364110-5198CB66-08D3-44AE-B415-8616E97AA5D0Q36407378-1CE1A678-B6AC-4EB5-82EE-BC2F4CD61E81Q36707731-CAAEC344-2DFA-4F10-ADD2-C1DC2BDA9525Q36802885-870257E0-3C12-417E-92D8-02D19A438B69Q37024667-3CF293C0-3721-49F8-82CC-D4E85BEED2FDQ37059387-95F85742-11B5-4923-8D48-B917CE8A120BQ37111141-183D471E-056D-445D-B7B6-157BC7A86253Q37166379-2B005F32-5946-4049-8303-3857AC92720E
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher ORCID ID = 0000-0002-4386-0292
@en
wetenschapper
@nl
研究者
@zh
name
Suzanne Kamel-Reid
@ast
Suzanne Kamel-Reid
@en
Suzanne Kamel-Reid
@es
Suzanne Kamel-Reid
@nl
Suzanne Kamel-Reid
@sl
type
label
Suzanne Kamel-Reid
@ast
Suzanne Kamel-Reid
@en
Suzanne Kamel-Reid
@es
Suzanne Kamel-Reid
@nl
Suzanne Kamel-Reid
@sl
prefLabel
Suzanne Kamel-Reid
@ast
Suzanne Kamel-Reid
@en
Suzanne Kamel-Reid
@es
Suzanne Kamel-Reid
@nl
Suzanne Kamel-Reid
@sl
P106
P1153
7006391577
P21
P31
P496
0000-0002-4386-0292